Hematologic Oncology Update cover image

Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

Hematologic Oncology Update

00:00

Xanu and Calabrutinib: A Comparison

I think I've seen some data on the tolerability of Xanu and patients who are intolerant of a Cala, not too much. What about the other way? Do you see patients who don't tolerate Xanu and do tolerate a Cala? Yeah, so Xanabrutin has the 215 study and that's looked at two cohorts. So with Ibruttinib and with a Calabrut inib intolerance, that then switched to Xanu. Calabruts does not have any really data from Xanu to a Cala. All three are good drugs, I think we can switch between all three. But as we're starting with second generation inhibitors

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app